Related Experiment Video
Updated: Jun 22, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Aripiprazole in the treatment of Huntington's disease: a case series
Andrea Ciammola1, Jenny Sassone, Clarissa Colciago
1Department of Neurology and Laboratory of Neuroscience, "Dino Ferrari" Centre, University of Milan Medical School - IRCCS Istituto Auxologico Italiano, Milano, Italy. a.ciammola@auxologico.it
Objectives:
The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington's disease (HD).
Methods And Results:
Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions.
Conclusions:
Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted.
Related Concept Videos
Huntington Disease l: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Psychosis: Goals of Pharmacotherapy
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Antipsychotic Drugs: Typical and Atypical Agents
Drug Therapy
Antianxiety Medications